Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 1/20 | 0.44 |
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.37 |
| ▸ | MAOA | P21397 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | OGG1 | O15527 | 1/20 | 0.35 |
| ▸ | ANPEP | P15144 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1553955 | 1.00 | DPP4 (0.44) | DPP4HTR2ACYP2A6CYP1A2ALOX5 | |
| SCHEMBL1553953 | 1.00 | DPP4 (0.44) | DPP4HTR2ACYP2A6CYP1A2ALOX5 | |
| Hydrochloric Acid SCHEMBL17710303 | 0.98 | DPP4 (0.43) | DPP4HTR2ACYP2A6CYP1A2ALOX5 | |
| Hydrochloric Acid SCHEMBL18765813 | 0.98 | DPP4 (0.43) | DPP4HTR2ACYP2A6CYP1A2ALOX5 | |
| Hydrochloric Acid SCHEMBL15287423 | 0.98 | DPP4 (0.43) | DPP4HTR2ACYP2A6CYP1A2ALOX5 | |
| SCHEMBL1444985 | 0.87 | ANPEP (0.41) | CYP1A2ALOX15ANPEP | |
| SCHEMBL30200359 | 0.85 | DPP4 (0.36) | DPP4HTR2ACYP1A2ALOX5ALDH1A1 | |
| SCHEMBL389437 | 0.82 | DPP4 (0.42) | DPP4HTR2ACYP2A6CYP1A2ALOX5 | |
| SCHEMBL22690052 | 0.82 | DPP4 (0.42) | DPP4HTR2ACYP2A6CYP1A2ALOX5 | |
| SCHEMBL389436 | 0.82 | DPP4 (0.42) | DPP4HTR2ACYP2A6CYP1A2ALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025125295-A1 | THIENO-INDOLE AMIDE DERIVATIVES AS PHGDH INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2025-06-19 | — | — | WO | disclosed |
| CN-114174245-B | Synthesis method of non-racemized cyclohexene | 巴斯夫公司 | 2024-05-10 | — | — | CN | disclosed |
| WO-2023239645-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2023-12-14 | — | — | WO | disclosed |
| WO-2023239645-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2023-12-14 | — | — | WO | disclosed |
| CN-116515782-A | Amine dehydrogenase mutant and application thereof in chiral amine alcohol compound synthesis | 中国科学院天津工业生物技术研究所 | 2023-08-01 | — | — | CN | disclosed |
| CN-114836486-B | Method for synthesizing chiral beta-amino alcohol by enzyme catalysis | 湖北大学 | 2023-05-12 | — | — | CN | disclosed |
| CN-115867554-A | BRM targeting compounds and related methods of use | 普莱鲁德疗法有限公司 | 2023-03-28 | — | — | CN | disclosed |
| US-20220281838-A1 | N-METHYL, N-(6-(METHOXY)PYRIDAZIN-3-YL) AMINE DERIVATIVES AS AUTOTAXIN (ATX) MODULATORS FOR THETREATMENT OF INFLAMMATORY AIRWAY OR FIBROTIC DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2022-09-08 | — | — | US | disclosed |
| CN-114836486-A | Method for synthesizing chiral beta-amino alcohol by enzyme catalysis | 湖北大学 | 2022-08-02 | — | — | CN | disclosed |
| CN-114174245-A | Synthetic method of non-racemic cyclohexene | 巴斯夫公司 | 2022-03-11 | — | — | CN | disclosed |
| EP-3731869-A1 | IRAK DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2020-11-04 | — | — | EP | disclosed |
| EP-3684366-A1 | CRBN LIGANDS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2020-07-29 | — | — | EP | disclosed |
| WO-2019060693-A1 | CRBN LIGANDS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2019-03-28 | — | — | WO | disclosed |
| EP-2643313-B9 | QUINAZOLINE CARBOXAMIDE AZETIDINES | MERCK PATENT GMBH (DE) | 2017-02-22 | — | — | EP | disclosed |
| EP-2643313-B1 | QUINAZOLINE CARBOXAMIDE AZETIDINES | MERCK PATENT GMBH (DE) | 2016-06-29 | — | — | EP | disclosed |
| CN-103228649-B | Quinazoline methane amide azetidine | MERCK PATENT GMBH (DE) | 2015-11-25 | — | — | CN | disclosed |
| US-8946247-B2 | Quinazoline carboxamide azetidines | MERCK PATENT GMBH (DE) | 2015-02-03 | — | — | US | disclosed |
| EP-2643313-A1 | QUINAZOLINE CARBOXAMIDE AZETIDINES | Merck Patent GmbH (DE) | 2013-10-02 | — | — | EP | disclosed |
| US-20130252942-A1 | QUINAZOLINE CARBOXAMIDE AZETIDINES | MERCK PATENT GMBH (DE) | 2013-09-26 | — | — | US | disclosed |
| WO-2012069146-A1 | QUINAZOLINE CARBOXAMIDE AZETIDINES | MERCK PATENT GMBH (DE) | 2012-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220281838-A1 | N-METHYL, N-(6-(METHOXY)PYRIDAZIN-3-YL) AMINE DERIVATIVES AS AUTOTAXIN (ATX) MODULATORS FOR THETREATMENT OF INFLAMMATORY AIRWAY OR FIBROTIC DISEASES | ENPP2, MYT1, INMT | DPP4 2806/4885HTR2A 491/4885CYP2A6 3357/4885 |
| US-20130252942-A1 | QUINAZOLINE CARBOXAMIDE AZETIDINES | AZI2, NQO2, ABL1 | DPP4 1055/4885HTR2A 446/4885CYP2A6 1219/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.